Trial Profile

V501 Phase II Efficacy Study in Women Aged 18 to 26

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme

Most Recent Events

28 Jun 2010 Actual patient number (1021) added as reported by ClinicalTrials.gov.
17 Dec 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com